Vida seeking bigger deals, cures with $600M fund

As Vida Ventures prepares to deploy its $600 million second fund, the firm believes its larger investments in biotech megarounds can continue to be good bets.

Vida, whose team includes several former members of Kite Pharma Inc.’s management team, has already realized four liquidity events from its $255 million first fund, which closed in November 2017. One, the $372.6 million IPO of Allogene Inc. (NASDAQ:ALLO) in October 2018, followed a $300 million series A round announced just six months prior, and was the second-largest biotech listing on NASDAQ in 2018....